COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study on the Effects of Botulinum Toxin Type A on Back Muscle in Chronic Low Back Pain

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00246155
Recruitment Status : Completed
First Posted : October 30, 2005
Last Update Posted : July 26, 2019
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to analyse the changes in back muscle size and strength following use of Dysport®, and to establish whether there is any association between pain reduction and change in strength, in patients suffering from chronic low back pain.

Condition or disease Intervention/treatment Phase
Low Back Pain Biological: Botulinum toxin type A Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 35 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective Study to Evaluate the Potential Effects on Function and Size in Back Muscle After Injection of Botulinum Toxin Type A (Dysport®) in the Treatment of Chronic Low Back Pain
Study Start Date : January 2005
Actual Primary Completion Date : July 1, 2005
Actual Study Completion Date : July 1, 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Back Pain Botox

Intervention Details:
  • Biological: Botulinum toxin type A
    Other Name: AbobotulinumtoxinA (Dysport®)

Primary Outcome Measures :
  1. Pain reduction as assessed by the mean Visual Analogue Scale (VAS) during last 2 weeks. Assessments will be made at the initial time before injection and 1, 2, 3 months after injection.
  2. Improvement in daily life activities and quality of life using the Oswestry Low Back Pain Questionnaire (OLBPQ), and Short Form-36 (SF-36). Assessments will be made at the initial time before injection and 1, 2, 3 months after injection.

Secondary Outcome Measures :
  1. Changes of the total isometric lumbar extensor strength and separated angle using lumbar MedX machine.
  2. Association between pain reduction and strength. Measurements will be performed at baseline, and 1, 2, 3 months after injection.
  3. Change of the lumbar extensor muscular size in CT Measurement will be performed at baseline and 3 months after injection.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Suffering from muscular low back pain (between L-1 and S-1 level).
  • Symptoms of more than six months duration.
  • No benefit from previous treatments.
  • Patient must present with bilaterally more than 2 active trigger points (TrPs) in the region of the low back musculature.
  • CT scan or MRI examination of the lumbar spine was performed within the past year.
  • Absence of significant pathology, such as bone fracture, nerve damage or severe psychiatric condition.

Exclusion Criteria:

  • Constant or persistent severe pain due to nerve root compression or fibromyalgia.
  • The patient has received surgery on the spine.
  • Other musculoskeletal disabilities e.g. myasthenia gravis, or disorders of the neuromuscular junction.
  • Any serious pathology, such as cancer, systemic inflammatory disease, vertebral fractures, neurological signs, spinal infection.
  • Epidural injection of local anaesthetics and steroids within 12 weeks proceeding inclusion.
  • Trigger point injection of local anaesthetics and steroid within 8 weeks proceeding inclusion.
  • Pain associated with urinary tract infections, or gynaecological disorders.
  • Bleeding disturbances or currently using coumarin derivatives.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00246155

Layout table for location information
Korea, Republic of
Wooridul Spine Hospital
Seoul, Korea, Republic of, 135-100
Sponsors and Collaborators
Layout table for investigator information
Study Director: Ipsen Medical Director Ipsen

Layout table for additonal information
Responsible Party: Ipsen Identifier: NCT00246155    
Other Study ID Numbers: A-38-52120-103
First Posted: October 30, 2005    Key Record Dates
Last Update Posted: July 26, 2019
Last Verified: July 2019
Keywords provided by Ipsen:
Additional relevant MeSH terms:
Layout table for MeSH terms
Back Pain
Low Back Pain
Neurologic Manifestations
Signs and Symptoms
Botulinum Toxins
Botulinum Toxins, Type A
Acetylcholine Release Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Neuromuscular Agents
Peripheral Nervous System Agents